(Total Views: 160)
Posted On: 02/03/2017 1:08:01 PM
Post# of 72446
Reminder why CTIX is running the K-OC trial.
“This will be a small trial that will move quickly with the end goal to provide the critical data necessary to forge a partnership with a large pharmaceutical company interested in co-developing Kevetrin as it makes progress toward possibly becoming the first p53-activating drug approved by the FDA.”
http://www.cellceutix.com/press-release/2016/...pline-data
"As far as our cancer program with Kevetrin, we believe that the position for partnering will be once we have data from our small Phase 2a study that is in preparation aimed to firmly establish the p53 modulation in the tumor as the mechanism of action and as we transition into oral dosing formulation. As far as timelines for potential partners, it's inappropriate for management to discuss that. It is more prudent for us to take into consideration what a potential partner wants and make that happen. "
http://seekingalpha.com/article/4023682-cellc...art=single
“This will be a small trial that will move quickly with the end goal to provide the critical data necessary to forge a partnership with a large pharmaceutical company interested in co-developing Kevetrin as it makes progress toward possibly becoming the first p53-activating drug approved by the FDA.”
http://www.cellceutix.com/press-release/2016/...pline-data
"As far as our cancer program with Kevetrin, we believe that the position for partnering will be once we have data from our small Phase 2a study that is in preparation aimed to firmly establish the p53 modulation in the tumor as the mechanism of action and as we transition into oral dosing formulation. As far as timelines for potential partners, it's inappropriate for management to discuss that. It is more prudent for us to take into consideration what a potential partner wants and make that happen. "
http://seekingalpha.com/article/4023682-cellc...art=single
(6)
(0)
